Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Uveal Melanoma
Cutaneous Melanoma
Colorectal Cancer
Other Solid Tumors

Interventions

DRUG: IDE196
DRUG: Binimetinib
DRUG: Crizotinib

Sponsor

IDEAYA Biosciences